Boston Scientific Scimed, Inc.

Cardiac Pacemakers, Inc.

Thomas J Herbst

Craig Michael Stolen

Lynne E Swanson

Bryan Allen Clark

Kimberly A Jorgensen

Arthur J Foster

Mark W Boden

Lili Liu

Sandra Nagale

Eric M Schneider

Candace Rhodes

Barbara Huibregtse

Candace A Rhodes

A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Methods for producing cardiomyocyte cells

In one aspect, the present disclosure is directed to methods of treating various conditions including bladder conditions in a patient, comprising: positioning at least one ablative element of an ablative device on or over an adventitial surface of the bladder; and using the ablative device to denervate bladder nerve fibers. Other aspects of the present disclosure pertain, for example, to devices and kits for of treating bladder conditions.

Bladder treatment by ablative denervation

A device for producing a trabecular fiber within a ventricle of a heart. The device includes a substrate and a first tissue anchor connected to the substrate. The substrate is formed of a non-rigid material.

Methods and devices for producing trabecular fibers

This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.

Systems and methods to reduce injury in the heart

Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Shunting of dietary lipids including cholesterol

Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system, through the gastrointestinal system, or redirected outside the body. The device may include a valve to control a flow of the fluid. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being metabolized and absorbed, thereby reducing the total caloric load to assist in weight management and/or for prevention/treatment of atherosclerosis.

Devices and methods for controlling dietary lipid uptake

Described is an implantable medical device comprising housing having a distal end and a proximal end, the proximal end fixedly coupled to the distal end of the lead body, a coupler rotatably disposed within the housing, the coupler having a proximal end and a distal end, and a helical electrode fixedly secured to the distal end of the coupler. The helical electrode comprises a proximal axial length portion that comprises a non-degradable material, and a distal axial length portion that comprises a biodegradable material. The proximal and distal portions may include concave/convex surfaces or threaded portions. The coupler and the helical electrode are configured to rotate and therefore translate relative to the housing.

Implantable active fixation lead with biodegradable helical tip

Described is an implantable lead comprising a flexible body extending between a proximal end and a distal end and a distal assembly coupled to the distal end of the body. The distal assembly includes a housing having a distal end and a proximal end, the proximal end fixedly coupled to the distal end of the lead body, a coupler rotatably disposed within the housing, the coupler having a proximal end and a distal end, and a helical electrode fixedly secured to the distal end of the coupler. The helical electrode comprises a proximal axial length portion that comprises a non-degradable material, and a distal axial length portion that comprises a biodegradable material. The coupler and the helical electrode are configured to rotate and therefore translate relative to the housing.

Growing community of inventors

Coon Rapids, MN, United States of America

Thomas J Herbst